-
Product Insights
Sicca Syndrome (Sjogren) – Drugs In Development, 2023
Global Markets Direct’s, ‘Sicca Syndrome (Sjogren) - Drugs In Development, 2023’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Malaria – Drugs In Development, 2023
Global Markets Direct’s, ‘Malaria - Drugs In Development, 2023’, provides an overview of the Malaria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hematological Disorders Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hematological Disorders Pipeline Market Report Overview The hematological disorders pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Hemostasis Tests ·       Coagulation Analyzers ·       Special Coagulation Tests ·       Hematology Tests ·       General Coagulation Tests Key...
-
Company Insights
F. Hoffmann-La Roche Ltd – Digital Transformation Strategies
Roche Digital Transformation Strategies Report Overview Hoffmann La Roche Ltd (Roche) has been focusing on using cloud, artificial intelligence, and data science to digitally transform its operations. The annual ICT spending of Roche was estimated at $3.1 billion for 2023. A major share of this spending is earmarked for acquiring network and communications, ICT services, and hardware from vendors. Roche is a healthcare company that develops drugs and diagnostics devices for treating diseases. It provides medicines and diagnostics for oncology,...
-
Macroeconomic Analysis
Spain PESTLE Insights – A Macroeconomic Outlook Report
Financial intermediation, real estate, and business activities contributed 24.9% to the gross value added (GVA) in 2022, followed by wholesale, retail, and hotels (17.9%) and mining, manufacturing, and utilities (17.0%). In nominal terms, the three sectors are forecast to grow by 4.3%, 4.7%, and 4.2%, respectively, in 2023. Four major autonomous communities of Spain generated around 78.1% of GDP in 2021 and were home to 74.7% of the population in 2022, according to Eurostat.
-
Product Insights
Lonza/ Sanofi – Ibex Solutions Biopharmaceutical Factory – Valais
Equip yourself with the essential tools needed to make informed and profitable decisions with our Lonza/ Sanofi - Ibex Solutions Biopharmaceutical Factory - Valais report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
ZESCO – Ibex 132/11 kV Substation and 11 kV Switching Station Lot 2 – Lusaka
Equip yourself with the essential tools needed to make informed and profitable decisions with our ZESCO - Ibex 132/11 kV Substation and 11 kV Switching Station Lot 2 - Lusaka report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...